Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment
暂无分享,去创建一个
[1] B. Andersen. Biobehavioral outcomes following psychological interventions for cancer patients. , 2002, Journal of consulting and clinical psychology.
[2] W. Symmans,et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] G. Davison,et al. Immune reconstitution following hematopoietic stem-cell transplantation. , 2001, Cytotherapy.
[4] L. Milas,et al. Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. , 2001, International journal of oncology.
[5] J. Gołąb,et al. Immunomodulation by anticancer chemotherapy: more is not always better (review). , 2001, International journal of oncology.
[6] B. Melichar,et al. THE PERIPHERAL BLOOD LEUKOCYTE PHENOTYPE IN PATIENTS WITH BREAST CANCER: EFFECT OF DOXORUBICIN/PACLITAXEL COMBINATION CHEMOTHERAPY , 2001, Immunopharmacology and immunotoxicology.
[7] A. Tong,et al. Cellular Immune Profile of Patients With Advanced Cancer Before and After Taxane Treatment , 2000, American journal of clinical oncology.
[8] Li-xi Yang,et al. The immunological effects of taxanes , 2000, Cancer Immunology, Immunotherapy.
[9] A. Kaider,et al. Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy. , 2000, Urology.
[10] J. Sparano. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. , 2000, Clinical breast cancer.
[11] G. Sledge,et al. Breast cancer: challenges and opportunities. , 1999, Seminars in oncology.
[12] C. Hudis. The current state of adjuvant therapy for breast cancer: focus on paclitaxel. , 1999, Seminars in oncology.
[13] M. Koci,et al. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. , 1998, Immunopharmacology and immunotoxicology.
[14] R. MacCallum,et al. Stress and immune responses after surgical treatment for regional breast cancer. , 1998, Journal of the National Cancer Institute.
[15] S. Goyert,et al. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. , 1997, Journal of immunology.
[16] K. HayGlass,et al. Comparison of [3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. , 1995, Journal of immunological methods.
[17] M. Christian,et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Wharton,et al. Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions. , 1994, Gynecologic oncology.
[19] J. Kiecolt-Glaser,et al. Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults. , 1994, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[20] J. Wharton,et al. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. , 1994, Cancer research.
[21] B. Andersen. Psychological interventions for cancer patients to enhance the quality of life. , 1992, Journal of consulting and clinical psychology.
[22] J. Ritz,et al. Biology and clinical relevance of human natural killer cells. , 1990, Blood.
[23] J. Kiecolt-Glaser,et al. Methodological issues in behavioral immunology research with humans , 1988, Brain, Behavior, and Immunity.
[24] J. Manfredi,et al. Taxol binds to cellular microtubules , 1982, The Journal of cell biology.
[25] B. Schöbitz. Steroids and central regulation of the immune response , 1994 .